Development of Resistance-Associated Mutations After Sotrovimab Administration in High-risk Individuals Infected With the SARS-CoV-2 Omicron Variant.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 35913747.
- Also identified by DOI 10.1001/jama.2022.13854 and PMC identifier 9344387.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study investigates whether resistance-associated mutations develop after treatment with sotrovimab in high-risk patients infected with the SARS-CoV-2 Omicron variant.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Antibodies, Neutralizing
- COVID-19
- Drug Resistance, Viral
- SARS-CoV-2
- COVID-19 Drug Treatment